In the next 3 years, the domestic pharmaceutical industry will present three major trends

According to the "China's large health industry strategic planning and enterprise strategic consulting report" statistics show that by 2017, China's large health industry has reached 6.2 trillion yuan, according to the development trend in recent years, china's large health industry is expected to reach 14.09 trillion yuan in 2023, and the industry will continue to grow rapidly and steadily.
background, industry analysts believe that in the next 3 years, the domestic pharmaceutical industry may show these three major trends.
In the next 3 years, the domestic pharmaceutical industry will present three major trends in innovation into pharmaceutical enterprises development momentum In recent years, the state in the policy and financial support for research and development in the background of increasing, many enterprises have consciously increased investment in research and development.
the continuous deepening of drug collection, pharmaceutical companies will put technological innovation in the core element of the position.
when "source innovation" returns to the pharmaceutical industry, innovative enterprises will have more advantages to gain opportunities for growth and development.
that are already at the forefront will continue to adjust their business models and transition to more balanced and scientific diversification.
, but it's worth noting that in the innovation process, companies should try to avoid stacking hot targets.
that PD-1, as a broad-spectrum anti-tumor therapy, has attracted many pharmaceutical companies at home and abroad.
last year, a total of five PD-1 drugs were approved for the market, two of which were imported and three were domestic.
addition, there are a large number of enterprises are being laid out.
domestic alternative imports are well known, China is a large generic drug country, more than 5000 pharmaceutical companies, 99% are generic pharmaceutical enterprises;
at present, generic drugs are the main body of China's pharmaceutical market, but under the influence of the "4 plus 7" volume procurement, medical insurance control fees and other policies, generic drugs are constantly facing the pressure of product sales, price decline.
in this process, many generic excess capacity began to be eliminated, but a number of high-quality generic drugs are also realizing the domestic replacement of the original drug.
industry believes that, in this context, with the expansion of the pharmaceutical industry, as well as the production enterprises continue to add, market competition will become more intense.
at the same time, domestic pharmaceutical enterprises in the domestic market to carry out import substitution, but also will gradually enhance the international market share, to overseas markets.
future, building comprehensive competitiveness will be the long-term trend and direction of the industry.
Domestic pharmaceutical companies to the international market in recent years, in the context of globalization and research and development fever, more and more domestic pharmaceutical companies frequently with foreign pharmaceutical companies to carry out transactions, on the one hand, access to the international advanced level of drugs in the domestic research and development, production or sales rights, on the other hand, there are many enterprises through cooperation and transactions began to China's independent research and development of new drugs to the world.
incomplete statistics show that in the past decade, domestic pharmaceutical companies authorized overseas projects, drug early research and development cooperation projects 111 projects, development-commercialization licenses reached 104.
note that there has been a marked increase in out-of-country projects over the past five years, reaching 15 in 2018.
, Hengrui is the typical representative of Chinese pharmaceutical companies going out in recent years, in January 2018, Hengrui authorized BTK inhibitors SHR-1459, SHR-1266 to TG Therapeutics, JAK1 inhibitors SHR-0302 to Arcutis, with a total transaction value of $350,223 million.
April 2020, Henrui signed an agreement with CG Korea to license the Karelli Pearl project to CG gong for a total transaction value of $87.75 million, while obtaining a share of CG's sales.
, since China's accession to the WTO in 2001, China's pharmaceutical industry has ushered in a period of great development.
from the early export of pharmaceutical raw material intermediates, to the export of chemicals and biologics, to the overseas licensing of innovative drugs in recent years and the U.S. listing of Zebtini, the international participation of Chinese pharmaceutical companies has been increasing.
this background, I believe that there will be more and more g high-quality domestic drugs to go out and flower all over the world.